DAEJEON, Korea, TORONTO & SAN DIEGO--(BUSINESS WIRE)--PharmAbcine, a private biotechnology company focused on the discovery and development of novel bi-specific antibodies, today announced a new global licensing deal with Triphase Accelerator Corporation for a fully human, bi-specific antibody targeting VEGFR-2/TIE 2. The agreement provides Triphase with global development and commercial rights, while PharmAbcine retains rights to China and Korea. The deal included undisclosed upfront, milestone and royalty payments.
“We are very excited about this deal with Triphase Accelerator,” said Jin-San Yoo, founder, president and CEO of PharmAbcine. “The team at Triphase has proven to be a successful and rapid developer of well-differentiated products in an innovative business model, and we look forward to working with them on the development of this novel, bi-specific antibody targeting VEGFR-2 and TIE 2.”
Help employers find you! Check out all the jobs and post your resume.
